MicroRNA-21, microRNA-181a and microRNA-196a as potential biomarkers in adult Egyptian patients with systemic lupus erythematosus.
Dysregulation of miRNAs has been described in systemic lupus erythematosis (SLE), however the clinical relevance of using miRNAs as biomarkers for SLE or predictors of disease progression is poorly investigated. This study investigated the expression signature of plasma miR-21, miR-181a and miR-196a among seventy SLE patients with different systemic lupus erythematosis disease activity index (SLEDAI) scores and thirty healthy controls using quantitative real-time PCR. Plasma IL-10 level was also measured in patients and control groups. The expression levels of all selected miRNAs were significantly increased in SLE patients as compared to healthy controls. MiR-196a was superior to differentiate patients from controls, whereas miR-21 was superior to discriminate mild from severe patients. Multivariate logistic analysis revealed miR-196a as independent predictor SLE diagnosis, it also suggest the strength of miR-21 and miR-196a as predictive biomarkers for development of SLE from mild severe form. Plasma IL-10 level was higher in SLE patients than in controls but it was not correlated with disease activity however; it showed a significant correlation with miR-21 expression. These miRNAs represent potential biomarkers in SLE. MiR-21 could serve as predictor of disease progression, while MiR-196a emerges as a novel valuable biomarker to predict both SLE risk and progression, this would be a critical tool for personalizing therapy and to avoid irreversible organ damage associated with SLE.
Department of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Tarek K
TK
Motawi
Department of Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Dahlia A
DA
Mohsen
Department of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Shohda A
SA
El-Maraghy
Department of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt. Electronic address: monakortam@hotmail.com.
Mona A
MA
Kortam
D000328:Adult; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D003710:Demography; D018450:Disease Progression; D004534:Egypt; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D016753:Interleukin-10 / Q000097:blood; D016015:Logistic Models; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000235:genetics*; D008297:Male; D035683:MicroRNAs / Q000097:blood / Q000235:genetics*; D011237:Predictive Value of Tests; D012372:ROC Curve; D012307:Risk Factors
D015415:Biomarkers; C000608460:MIRN-181 microRNA, human; C542543:MIRN196 microRNA, human; C524940:MIRN21 microRNA, human; D035683:MicroRNAs; D016753:Interleukin-10
SLE; SLEDAI; miR-181a; miR-196a; miR-21